Construction method of mouse ejection fraction retention type heart failure model

The NOS3 gene was knocked out through CRISPER-CAS9 technology and fed high-fat feed to construct a mouse model of ejaculation fraction-retaining heart failure, which solved the problem that the existing technology was difficult to simulate HFpEF, and achieved good simulation of the clinical characteristics of HFpEF, making the disease Mechanism exploration and treatment methods provide the basis.

CN118995829APending Publication Date: 2024-11-22TONGJI HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI TECH

Patent Information

Application Number
CN202411025500.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-29
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

The prior art is difficult to effectively simulate animal models of ejection fraction-retaining heart failure (HFpEF), and the lack of effective treatment methods affects the exploration of the mechanism and treatment methods of the disease.

Method used

The mouse NOS3 gene was knocked out by CRISPER-CAS9 technology and fed it with high fat feed to construct an ejection fraction-retaining heart failure mouse model to simulate the clinical characteristics of HFpEF, such as hypertension, metabolic disorders, cardiac fibrosis and inflammation. wait.

Benefits of technology

A mouse model of ejection fraction-retaining heart failure with both hypertension and metabolic disorders was successfully constructed, showing the vast majority of clinical characteristics of HFpEF, providing a solid foundation for exploring disease mechanisms and developing therapeutic methods.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118995829A_ABST
    Figure CN118995829A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of medical animal models. The invention provides a construction method of a mouse ejection fraction retention type heart failure model, which comprises the following steps: (1) knocking out a mouse NOS3 gene by using a CRISPER-CAS9 technology to obtain a NOS3 gene knockout mouse; and (2) feeding the obtained NOS3 gene knockout mouse with high-fat feed to obtain the NOS3 gene knockout mouse. The ejection fraction retention type heart failure mouse model constructed and obtained through the novel method has good performance in the aspects of obesity and hypertension phenotypes, systolic and diastolic functions, cardiac fibrosis degree, mitochondrial morphology and functions, inflammation and the like. And a solid foundation is laid for later HFpEF mechanism exploration.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of medical animal models, and in particular to a method for constructing a mouse heart failure model with preserved ejection fraction. Background Art

[0002] Heart failure is a serious life-threatening clinical syndrome. The global prevalence of heart failure in adults exceeds 2%, and is expected to reach 3% by 2030. According to statistics, the one-year mortality rate of patients with heart failure is about 20%, and the five-year mortality rate is 50%. The latest heart failure guidelines of the American Heart Association in 2022 divide heart failure into three types according to left ventricular ejection fraction and medical history: heart failure with reduced ejection fraction (HFrEF, LVEF≤40%), heart failure with mildly reduced ejection fraction (HFmrEF, 40%<LVEF<49%), and heart failure with preserved ejection fraction (HFpEF, LVEF≥50%). Among them, HFpEF has become the main type of heart failure, specifically referring to increased myocardial stiffness and impaired cardiac diastolic function, but unchanged ejection fraction. In Asia, the proportion of HFpEF is relatively high, accounting for approximately 35% to 45% of all heart failure. In China, according to the 2023 Chinese Expert Consensus on the Diagnosis and Treatment of Heart Failure with Preserved Ejection Fraction, HFpEF accounts for nearly 50% of heart failure patients.

[0003] The inflammation and metabolic disorders of HFpEF involve multiple organs outside the heart, including the liver, lungs, and kidneys. The causes and treatments of HFpEF are complex, and many drugs that are effective for HFrEF have no significant effect on HFpEF. Except for the recently proposed SGLT2 inhibitors and GLP-1 receptor agonists, there are currently no effective drugs to treat HFpEF. Therefore, there is an urgent need to understand the mechanisms of HFpEF and find effective treatments. Summary of the invention

[0004] The purpose of the present invention is to provide a method for constructing a mouse model of heart failure with preserved ejection fraction. The mouse model of heart failure with preserved ejection fraction constructed by the novel method has good performance in obesity and hypertension phenotypes, systolic and diastolic function, degree of cardiac fibrosis, mitochondrial morphology and function, and inflammation, which lays a solid foundation for the later exploration of the mechanism of HFpEF.

[0005] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:

[0006] The present invention provides a method for constructing a mouse heart failure model with preserved ejection fraction, characterized in that it comprises the following steps:

[0007] (1) Using CRISPER-CAS9 technology to knock out the mouse NOS3 gene and obtain NOS3 knockout mice;

[0008] (2) The obtained NOS3 gene knockout mice were fed with a high-fat diet.

[0009] Preferably, the gRNA sequence in the CRISPER-CAS9 technology in step (1) includes a forward primer gRNA1 and a reverse primer gRNA2.

[0010] Preferably, the sequence of the forward primer gRNA1 is shown as SEQ ID NO.1, and the sequence of the reverse primer gRNA2 is shown as SEQ ID NO.2.

[0011] Preferably, the mice are C57BL / 6N mice, 7-9 weeks old.

[0012] Preferably, the high-fat feed in step (2) is high-fat feed D12492, and the fat calories are 60 kcal%.

[0013] Preferably, the feeding period in step (2) is 7-9 weeks.

[0014] By adopting the above technical solution, the present invention has the following beneficial effects:

[0015] 1. The mouse model of heart failure with preserved ejection fraction constructed by the novel method of the present invention has two key factors, hypertension and metabolic disorder, and can simulate most of the clinical characteristics of patients with the disease. It has good performance in obesity and hypertension phenotype, systolic and diastolic function, degree of cardiac fibrosis, mitochondrial morphology and function, and inflammation.

[0016] 2. In the experiment of the present invention, CRISPER-CAS9 technology was used to obtain NOS3 gene knockout mice and high-fat diet to construct HFpEF mouse model. The weight, blood pressure, glucose tolerance and exercise distance of the HFpEF group mice were more significantly changed than those of the control group; diastolic function decreased, systolic function remained unchanged; myocardial hypertrophy and cardiac fibrosis were significantly aggravated; mitochondrial swelling, cristae rupture and vacuolization were aggravated; inflammation and oxidative stress were significantly aggravated. GSEA analysis found that cytokines and chemokines play an important role in the development of the disease, which is consistent with the vast majority of clinical characteristics of patients with the disease. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] Figure 1 This is a diagram of the NOS3 gene knockout strategy;

[0018] Figure 2 This is a graph of PCR results to verify the mouse genotype;

[0019] Figure 3 The general data of mice in different treatment groups ( Figure 3 A in the figure is the general figure and the general figure of the heart, and the horizontal line represents 1 cm; B is the change of body weight, C is the change of exercise distance, D is the lung wet-to-dry weight ratio, and E is the ratio of heart weight to tibia length; ** represents P < 0.01);

[0020] Figure 4 The cardiac ultrasound data of mice in different treatment groups ( Figure 4 A in the figure is a representative ultrasound image in M-mode, PW and Tissue mode, B is the change of left ventricular ejection fraction, C is the shortening rate of left ventricular minor axis, and D is the peak velocity of mitral blood flow E divided by the average value of the early diastolic velocity of the lateral wall and septum at the mitral annulus E'; ** represents P < 0.01);

[0021] Figure 5 Schematic diagram of the dewaxing steps for paraffin sections;

[0022] Figure 6 Schematic diagram of the dehydration steps for HE staining of paraffin sections;

[0023] Figure 7 HE staining results and statistical graphs of mice in different treatment groups ( Figure 7 A in the figure is the staining result, and B is the statistical figure of muscle cell size; ** represents P < 0.01);

[0024] Figure 8 Schematic diagram of Masson staining differentiation and dehydration steps;

[0025] Fig. 9 The results and statistical graphs of Sirius red staining and Masson staining of mice in different treatment groups ( Fig. 9 A in the figure is the staining result, B is the statistical graph of perivascular fibrosis by Masson staining, and C is the statistical graph of perivascular fibrosis by Sirius red staining; ** represents P < 0.01);

[0026] Fig.10 Transmission electron microscopy images and statistical graphs of heart tissues of mice in different treatment groups ( Fig.10 A in the figure is a representative transmission electron microscopy image, and B is the percentage of damaged mitochondria with lost mitochondrial cristae in the total mitochondria; red arrows point to mitochondria, and ** represents P < 0.01);

[0027] Fig.11 Results of RNA expression in cardiac tissue of mice in different treatment groups ( Fig.11 A is TNF-α, B is IFN-γ, C is IL-6, D is IL-1β, and E is IL-18);

[0028] Fig.12 Transcriptome sequencing and data functional enrichment analysis results of different treatment groups ( Fig.12A represents the regulation of signal pathways, B represents cytokines, and C represents chemokines). DETAILED DESCRIPTION

[0029] The present invention provides a method for constructing a mouse heart failure model with preserved ejection fraction, comprising the following steps:

[0030] (1) Using CRISPER-CAS9 technology to knock out the mouse NOS3 gene and obtain NOS3 knockout mice;

[0031] (2) The obtained NOS3 gene knockout mice were fed with a high-fat diet.

[0032] In the present invention, the gRNA sequence in the CRISPER-CAS9 technology includes a forward primer gRNA1 and a reverse primer gRNA2. The sequence of the forward primer gRNA1 is shown in SEQ ID NO.1, and the specific sequence is CCCAGTCAGTCTGCCGTAACAGG; the sequence of the reverse primer gRNA2 is shown in SEQ ID NO.2, and the specific sequence is GGGCCTCCCGAAGCCAACACTGG.

[0033] In the present invention, the mouse is a C57BL / 6N mouse, and the age is preferably 7-9 weeks, and more preferably 8 weeks.

[0034] In the present invention, the obtained NOS3 gene knockout mice were fed with a high-fat diet, wherein the high-fat diet was high-fat diet D12492, and the fat calories of the high-fat diet were 60 kcal%.

[0035] In the present invention, the feeding period is preferably 7-9 weeks, and more preferably 8 weeks.

[0036] The technical solutions provided by the present invention are described in detail below in conjunction with the embodiments, but they should not be construed as limiting the protection scope of the present invention.

[0037] Example 1 Construction of Hypertension Model

[0038] There are three isoenzymes of nitric oxide synthase (NOS): endothelial NOS (eNOS), neuronal NOS (nNOS) and inducible NOS (iNOS). eNOS (gene name: NOS3) is mainly present in endothelial cells, and the NO generated by eNOS has the properties of vasodilation and anti-thrombosis. After knocking out the NOS3 gene, the endothelium-dependent vasodilation function of mice disappeared, blood pressure increased significantly, vascular remodeling was impaired, and cardiovascular events such as atherosclerosis and myocardial infarction were more likely to occur. Therefore, the NOS3 gene knockout (KO) mouse was successfully constructed using CRISPER-CAS9 technology, and the knockout effect was verified by PCR technology.

[0039] (A) Construction of NOS3 knockout (KO) mice

[0040] The target gene for editing, NOS3, was identified with NCBI ID 18127.

[0041] Design appropriate gRNA (guide RNA) according to the target gene sequence, which can pair with the specific region of the target gene. Using CRISPER-CAS9 technology, use the following gRNA sequence to knock out exons 2-13 of the NOS3 gene (such as Figure 1 ), thereby achieving the knockout of the NOS3 gene and successfully constructing NOS3 gene knockout mice. The gRNA sequence includes a forward primer gRNA1 and a reverse primer gRNA2, the sequence of the forward primer gRNA1 is shown in SEQ ID NO.1, and the specific sequence is 5'-CCCAGTCAGTCTGCCGTAACAGG-3'; the sequence of the reverse primer gRNA2 is shown in SEQ ID NO.2, and the specific sequence is 5'-GGGCCTCCCGAAGCCAACACTGG-3'. According to the above sequence, the target gene is knocked out to obtain F0 mice.

[0042] The gRNA was obtained by chemical synthesis by connecting CRISPR RNA (crRNA) and transcription activating crRNA (tracrRNA). The ratio of crRNA:tracrRNA:Cas9 was (1:1:1) to (5:5:1) at room temperature and incubated at room temperature for 10 minutes to form a Cas9 RNP complex.

[0043] The above gRNA plasmid is constructed, transcribed into RNA in vitro, and then injected into the pronucleus together with Cas mRNA to obtain F0 generation positive mice identified by sequencing. gRNA guides Cas9 protein to recognize and bind to the specific region of the target gene. Cas9 protein has nuclease activity and can cut the DNA of the target gene. Cells try to repair the cut DNA through non-homologous end joining (NHEJ) or homologous recombination (HDR).

[0044] Mouse breeding. F0 generation positive mice are mated with wild-type mice (WT) to obtain F1 generation heterozygous mice that are positive by PCR and sequencing. F1 generation mice with the same genotype from the same F0 generation mouse are selected, and after reaching sexual maturity, they are mated to obtain F2 generation mice. Theoretically, 25% of the F2 generation mice are homozygous mice with consistent knock-in sites, 50% are heterozygous mice with only one chromosome knocked in, and 25% are wild-type mice. Sufficient number of positive mice are obtained for subsequent experiments.

[0045] (II) Verification of the effect of NOS3 gene knockout

[0046] 1. Mouse Tail DNA Extraction

[0047] Number the bred mice 11±2 days after birth and cut their tails. The tail length is required to be 0.3±0.1cm. The tails can be stored in a -20℃ refrigerator for future use. Add 300μL lysis solution + 5μLPK (20mg / mL) to each sample and digest overnight at 55℃ (not less than 4h). Add 600μL (double volume) of -20℃ pre-cooled anhydrous ethanol for ethanol precipitation, turn upside down until the flocculent precipitate can be clearly seen. Centrifuge at 12000rpm for 5min. After centrifugation, pour out the upper liquid. Place it upside down on a piece of flat paper (note that it must be upright so that the liquid inside can flow to the EP tube mouth faster). After about 5-10min, change the upright tube to another position and press it down gently (the purpose is to use the flat paper to absorb the liquid gathered at the tube mouth, this step can save a lot of drying time). Wait for 30-60min until it is completely dry. At this time, the precipitate becomes transparent and the extracted DNA is of good quality. Add 200 μL MilliQ water or TE solution and shake up and down to fully dissolve the DNA.

[0048] 2. PCR verification of mouse genotype

[0049] Take 3 μL of DNA template and perform PCR in a 25 μL reaction system.

[0050] The primer sequences of the PCR are forward primer F1 and reverse primer R1. The sequence of the forward primer F1 is shown in SEQ ID NO.3, and the specific sequence is 5'-CACCCAAGAGGTTATTTCACTCAT-3'; the sequence of the forward primer R1 is shown in SEQ ID NO.4, and the specific sequence is 5'-CATCAGGTACTGAGCAGATGTGGA-3'.

[0051] The PCR reaction system contained 25 μL in total, including 9.0 μL of ddH2O, 1.0 μL of forward primer, 1.0 μL of reverse primer, 12.5 μL of Premix Taq and 1.5 μL of DNA template.

[0052] The PCR reaction conditions are as follows: ① Pre-denaturation: 94°C, 3 min. ② Denaturation: 94°C, 30 s; Annealing: 60°C, 35 s; Extension: 72°C, 35 s; 35 cycles in total. ③ Final extension: 72°C, 5 min.

[0053] ④Storage: 4℃.

[0054] 3. Electrophoresis

[0055] Prepare 1-3% agarose gel according to the target band, dissolve 1g-3g agarose in 100mL TAE buffer, heat in a microwave until the agarose melts, add 10μL nucleic acid dye (EB substitute), pour into the electrophoresis template, insert the comb, and use it after condensation. Add an appropriate amount of DNA to the agarose gel. It is recommended to add 10μL to the small hole and 20μL to the large hole. According to the size of the target band, select a suitable DNA marker and add it to the gel. Set the gel electrophoresis instrument to 120V voltage and run for 20-30min. Use a gel imaging system to observe and take pictures. Edit the gel image and generate a genotype identification result report.

[0056] The results are as follows Figure 2 As shown, each vertical lane represents each mouse, the result of the MT group (MT represents positive mice, i.e., the gene knockout is achieved) is 653bp, and the result of the WT group (ordinary mice, i.e., the knockout is not achieved) is 7859bp. If the gene is knocked out, a white band will appear around 653bp, and if the knockout fails, there will be no band.

[0057] Example 2 Metabolic Disorder Model

[0058] High-fat diet D12492 (60 kcal% fat) (purchased from Medison, item number MD12033) refers to a diet in which the calories provided by fat account for 60% of the total calories and the protein is at a normal level. This high-fat diet is widely used in obesity models and models of its complications, such as obesity models, insulin resistance models, type II diabetes models, metabolic syndrome models, etc.

[0059] Therefore, the HFpEF mouse model was constructed by using the above-mentioned NOS3 gene whole body knockout mice (KO) and feeding them with a high-fat diet (D12492, 60 kcal% fat) normally.

[0060] Example 3

[0061] 1. Animal husbandry and grouping

[0062] The mice used in the experiment were 8-week-old male C57BL / 6N mice, which were housed in the Pesticide Toxicology Research Center of Tongji Medical College, Huazhong University of Science and Technology. The experimental facility unit is SYXK (E) 2019-0046. The temperature of the breeding environment was set at 20-26°C, with a daily light / dark cycle of 12 hours, and sufficient water and food were provided. The animal experiment was approved by the Ethics Committee of the Experimental Animal Center of Tongji Medical College, Huazhong University of Science and Technology.

[0063] The animal experiment was divided into the following two groups: (1) 8-week-old SPF male C57BL / 6N wild-type mice (WT) were fed with normal diet for 8 weeks and served as the control group; (2) 8-week-old SPF male C57BL / 6NNOS3 knockout mice (KO) were fed with high-fat diet (D12492, 60 kcal% fat) for 8 weeks and served as the modeling group.

[0064] (II) Mouse phenotypic detection

[0065] The above mice were taken, and their body weight and movement distance were measured when they were 16 weeks old. Then, they were killed, their heart weight was weighed, their tibia length was measured, and the heart weight to tibia length ratio (HW / TL) and the wet-dry weight ratio of the lung tissue were calculated.

[0066] The results are as follows Figure 3 As shown, the mice in the HFpEF group were larger in body shape and heart, with significantly increased body weight and significantly decreased exercise distance than those in the control group; the heart-to-tibia length ratio of the mice in the HFpEF group was significantly increased, suggesting that they may have myocardial hypertrophy; the HFpEF group was significantly higher than that of the control mice, suggesting that they had pulmonary edema and obvious cardiac dysfunction.

[0067] (III) Cardiac ultrasound testing

[0068] In advance, remove the hair in the precordial area of ​​the mouse with a cotton swab dipped in depilatory cream, fix the mouse in a supine position on the test bench with tape, and apply a small amount of ultrasonic coupling agent to the limbs to ensure good contact with the electrodes of the test bench. After fixation, use isoflurane for continuous gas anesthesia with the help of a ventilator, adjust the dose of anesthetics to stabilize the heart rate of the mouse at 500-600bpm, apply an appropriate amount of ultrasonic coupling agent to the precordial area, and record long-axis and short-axis two-dimensional echocardiograms and M-mode echocardiograms to evaluate the cardiac contractile function of the mouse. Move the probe position to the apex of the heart, adjust the dose of anesthetics at the same time, control the heart rate of the mouse at 500bpm, and obtain the ratio of the peak blood flow velocity of the early diastolic blood flow of the left ventricle to the peak blood flow velocity of the late diastolic blood flow (E / A ratio), and the ratio of the peak blood flow velocity of the early diastolic blood flow of the mitral valve to the peak movement velocity of the early diastolic movement of the mitral valve ring (E / E' ratio) to evaluate the left ventricular diastolic function of the mouse.

[0069] The mice were examined by echocardiography before being killed. The results showed that there was no significant change in the systolic indexes of the mice, such as the left ventricular ejection fraction (LVEF) and the ventricular shortening fraction (LVFS); the diastolic indexes of the mice, such as the E / E' ratio, increased significantly, indicating that the mice only had diastolic dysfunction (such as Figure 4 ).

[0070] 4. Cardiac histological examination

[0071] 1. Changes in cardiomyocyte morphology

[0072] After killing the mice, the heart tissues were collected and embedded in paraffin for sectioning. The sections were stained with hematoxylin-eosin (HE) to observe the morphological changes of myocardial cells.

[0073] HE staining: (1) The paraffin sections were placed in an oven at 56°C for 30 minutes and then Figure 5 Dewax the sections according to the steps shown. (2) Wash with PBS three times, 2 minutes each time. (3) Bake the paraffin sections in a 56°C oven for 30 minutes, and then Figure 5 Dewaxing was performed as shown. (4) Draw a circle around the tissue with a tissue pen, add hematoxylin stain, stain for 3-8 minutes, wash 3 times in tap water, 2 minutes each time, differentiate with 1% hydrochloric acid alcohol for 10-15 seconds, wash 3 times in tap water, 2 minutes each time, then use 0.6% ammonia water to turn blue for 10-20 seconds, and rinse with running water. (5) Add eosin stain to stain the cytoplasm for 1-3 minutes. (6) Dehydration steps as shown. Figure 6 Finally, take out the slices from xylene, dry them slightly, and seal them with neutral gum.

[0074] By comparing the two groups of morphology, we can see that ( Figure 7 The cardiomyocytes of mice in the HFpEF group were significantly hypertrophic.

[0075] 2. Detection of cardiac fibrosis

[0076] The mouse heart tissues were stained with Sirius red and Masson to detect the degree of cardiac fibrosis.

[0077] Sirius red staining: (1) Figure 5 Dewax the slides as shown. (2) Wash twice with PBS, 5 minutes each time. (3) Draw circles with a tissue pen, add Sirius red stain, and incubate at room temperature for 1 hour. (4) Rinse with running water and seal the slides with neutral gum and coverslip.

[0078] Masson staining: (1) Figure 5 Dewaxing was performed according to the steps shown. (2) Soak the slices in Masson A solution (2.5% potassium dichromate mordant) for about 15 hours. (3) Incubate the slices soaked in Masson A solution (2.5% potassium dichromate mordant) in a 65°C oven for 30 minutes, and wash with tap water until the yellow color on the tissue fades (30 seconds). At the same time, preheat Masson D solution (Ponceau acid fuchsin) and Masson F solution (2.5% aniline blue solution) in the oven. (4) Mix equal volumes of Masson B solution and Masson C solution to prepare Weiger iron hematoxylin stain solution (prepare and use immediately), add the mixture to the tissue, stain for 1 minute, and rinse with running water. (5) Differentiate with 1% hydrochloric acid alcohol (concentrated hydrochloric acid: anhydrous ethanol = 1:100) for 1 minute until the cell nucleus is gray-black and the background is almost colorless or light gray. (6) Wash with tap water for 3 minutes, drain slightly, add Masson D solution (Ponceau acid fuchsin) and dye for 6 minutes until the tissue turns bright red. (7) Drain slightly, add Masson E solution (1% phosphomolybdic acid solution) and dye for 1-2 minutes until the collagen fibers turn light red. (8) Drain Masson E solution slightly, without washing, directly add Masson F solution (2.5% aniline blue solution) and dye for 2-30 seconds. (9) Differentiation and dehydration steps are as follows Figure 8 As shown, after drying slightly, seal the slide with neutral gum.

[0079] According to the two staining results, it can be seen that (such as Fig. 9 The degree of pericardial fibrosis in the HFpEF group was significantly higher than that in the control group.

[0080] 3. Cardiomyocyte Mitochondria Detection

[0081] Transmission electron microscopy was used to detect changes in the morphology and size of cardiomyocyte mitochondria.

[0082] The results are as follows Fig.10As shown, electron microscopy showed that the mitochondria of the cardiomyocytes in the control group were intact and dense, with no vacuoles inside the mitochondria; the mitochondria in the HFpEF model group were fragmented and swollen, the vacuolation inside the mitochondria was aggravated, and the percentage of mitochondria with lost cristae was significantly increased, indicating that the mitochondrial morphology of the hearts of mice in the HFpEF group was changed and the mitochondrial function was impaired.

[0083] 4. Inflammation and oxidative stress detection

[0084] WB and PCR techniques were used to detect changes in the transcriptional and protein levels of TNF-α, IFN-γ, IL-6, IL-1β, IL-18, and GAPDH molecules.

[0085] RNA extraction from cardiac tissue: (1) Take 1 / 6 of the tissue that has been ground into powder and place it in an EP tube that has been precooled in liquid nitrogen. (2) Add 500 μL Trizol to the EP tube, shake and mix, and place it at room temperature for 5 minutes. (3) Open the EP tube in a fume hood, add 100 μL chloroform to it, shake it on a vortex shaker for 15 seconds, and place it at room temperature for 5 minutes. (4) While standing, precool the low-temperature centrifuge to 4°C, set the centrifugal force to 10,000 g, and centrifuge at 4°C for 15 minutes. (5) After centrifugation, take out the EP tube and place it in an ice box. At this time, the liquid in the tube is divided into three layers. The upper layer is a colorless aqueous phase, in which RNA mainly exists, the middle layer is milky white, and the lower layer is a pink organic phase. Transfer the top colorless aqueous phase to a new EP tube, taking care to avoid sucking the middle layer. (6) Add an equal volume of isopropanol to the aqueous phase, invert and mix, and incubate at room temperature for 10 minutes. (7) Centrifuge at 10,000 g, 4°C for 15 minutes and discard the supernatant. (8) Add 500 μL of 75% ethanol (prepared with DEPC water) to the tube and shake vigorously. (9) Centrifuge at 7,500 g, 4°C for 5 minutes and discard the supernatant. A very small amount of white colloidal precipitate can be seen at the bottom of the tube. (10) Repeat the centrifugation in step (9), use a 10 μL micropipette to aspirate the remaining liquid, turn the EP tube upside down on a clean paper, and dry it at room temperature. (11) After drying, observe the amount of precipitation, add 20-40 μL of enzyme-free water to dissolve the precipitate, and vortex to mix. After mixing, use an ultra-micro nucleic acid analyzer to measure the RNA concentration and OD of each sample. 260 / 280 The value of .

[0086] Reverse transcription: (1) Prepare an appropriate amount of EP tubes, eight-tube strips and different types of gun tips in advance and sterilize them with high-pressure steam. (2) After RNA extraction is completed, the reverse transcription reaction should be carried out as soon as possible to avoid RNA degradation. To ensure the efficiency of reverse transcription, 1μg of RNA is generally taken when preparing the reaction system. Reverse transcription uses the reverse transcription kit of Wuhan Abotek Biotechnology Co., Ltd., and the reaction system is shown in Table 1. (3) The reverse transcription reaction is carried out on an ordinary PCR instrument, and the reaction program is set as follows: 25℃, 5 minutes→42℃, 15 minutes→85℃, 5 seconds→12℃, and keep it going. (4) After the reverse transcription is completed, the resulting cDNA product is stored in a -80℃ ultra-low temperature refrigerator.

[0087] Table 1 Reverse transcription reaction system

[0088]

[0089] Real-time fluorescence quantitative PCR: (1) Primer synthesis, the primer sequence is shown in Table 2. (2) Prepare an appropriate amount of EP tubes, eight-tube strips and various specifications of gun tips in advance, and sterilize them with high-pressure steam. (3) Take out the cDNA sample, primers and 2×SYBR Green Fast qPCRMix, and thaw them on ice. (4) Real-time fluorescence quantitative PCR uses the SYBR GreenFast qPCR Mix kit of Wuhan Abotek Biotechnology Co., Ltd., and the reaction system is shown in Table 3. (5) Calculate the sample amount and prepare the reaction system. Because there will be a certain amount of loss during the preparation process, leave a 10%-20% surplus when calculating the volume. To ensure the stability of the results, set three replicate wells for each sample and each indicator. All systems are prepared on ice using enzyme-free EP tubes or eight-tube strips. (6) After preparation, oscillate to mix, centrifuge instantly, and then transfer the liquid in the eight-tube strip to a 384-well plate dedicated to PCR and seal it with an optical sealing film. (7) Place the 384-well plate in a clean PE film glove and centrifuge at 2500 rpm for 5 minutes to prepare for loading. (8) The loading procedure is shown in Table 4. After loading, derive the Ct value and calculate 2 ^-ΔΔCt values ​​for statistical analysis.

[0090] Table 2 Primer sequence information

[0091]

[0092]

[0093] Table 3 Real-time fluorescence quantitative PCR reaction system

[0094]

[0095] Table 4 Real-time fluorescence quantitative PCR reaction program

[0096]

[0097] The results are as follows Fig.11 As shown, the transcription levels of TNF-α, IFN-γ, IL-6, IL-1β and IL-18 in the heart tissue of the control group and model group mice were significantly increased, indicating that the level of inflammation in the heart tissue of the model group mice was increased.

[0098] (IV) Transcriptome sequencing (Bulk-RNA seq)

[0099] The original sequence obtained by sequencing on the second-generation high-throughput sequencing platform is processed to obtain high-quality sequences by removing low-quality sequences and connector contamination. All subsequent analyses are based on clean reads. The transcriptome sequencing information analysis process is mainly divided into three parts: sequencing data quality control, data comparison analysis, and transcriptome deep analysis. Among them, sequencing data quality control includes filtering the sequences obtained by sequencing, evaluating the quality of sequencing data, and calculating the sequence length distribution. Data comparison analysis is mainly for the sequences aligned to the genome, and classification and feature analysis are performed in turn according to different genome annotation information, and the corresponding expression levels are calculated; then differential expression analysis is performed. Conventional transcriptome analysis also includes variable splicing analysis, new transcript prediction, variation analysis, deep analysis, and other personalized analysis.

[0100] Based on transcriptome sequencing and its data functional enrichment analysis results (such as Fig.12 ), and found that the HFpEF model group had significant regulation of multiple signaling pathways compared with the control group, including complement cascade, fatty acids, plasma lipoprotein remodeling, fibrinogen pathway, platelet degranulation, plasma calcium ion increase, etc. GSEA analysis found that cytokines and chemokines play an important role in the development of the disease. It is consistent with the vast majority of clinical characteristics of patients with this disease.

[0101] In summary, it can be seen that a new HFpEF mouse model was successfully constructed through the technical solution of the present invention, laying a solid foundation for the later exploration of the mechanism of HFpEF.

[0102] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. A method for constructing a mouse heart failure model with preserved ejection fraction, characterized in that: The steps include: (1) Using CRISPER-CAS9 technology to knock out the mouse NOS3 gene and obtain NOS3 knockout mice; (2) The obtained NOS3 gene knockout mice were fed with a high-fat diet.

2. The construction method according to claim 1, characterized in that: The gRNA sequence in the CRISPER-CAS9 technology in step (1) includes a forward primer gRNA1 and a reverse primer gRNA2; The sequence of the forward primer gRNA1 is shown as SEQ ID NO.1, and the sequence of the reverse primer gRNA2 is shown as SEQ ID NO.

2.

3. The construction method according to claim 1, characterized in that: The mice are C57BL / 6N mice, and are 7-9 weeks old.

4. The construction method according to claim 1, characterized in that: The high-fat feed in step (2) is high-fat feed D12492, and the fat calories are 60 kcal%.

5. The construction method according to claim 1, characterized in that: The feeding time in step (2) is 7-9 weeks.

Citation Information

Patent Citations

  • Method for constructing LCR gene knockout animal model based on CRISPR / Cas9 technology and application thereof

    CN115011637A

  • Galt gene knockout mouse model based on CRISPR-Cas9 system, construction method and application

    CN117568399A

  • Vasoprotective and cardioprotective antidiabetic therapy

    US20120121530A1

  • Transgenic animals having a disrupted endothelial nitric oxide synthase gene and methods of use

    WO1997033980A1

Cited By

  • Establishment method of heart failure mouse model with supernormal ejection fraction

    CN119969337A